$2.85
-0.08 (-2.57%)
Open$2.91
Previous Close$2.92
Day High$2.97
Day Low$2.81
52W High$11.88
52W Low$3.02
Volume—
Avg Volume77.7K
Market Cap63.77M
P/E Ratio—
EPS$-2.09
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+704.6% upside
Current
$2.85
$2.85
Target
$22.89
$22.89
$19.41
$22.89 avg
$38.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Net Income | 3.46M | 2.44M | 2.89M |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |
| Rev Growth | +16.8% | +12.7% | +4.6% |
| Debt/Equity | 0.77 | 0.70 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |